C4 Therapeutics, Inc.
CCCC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $249,732 | $280,469 | $288,284 | $1,482,544 |
| - Cash | $55,499 | $126,590 | $29,754 | $76,124 |
| + Debt | $65,756 | $70,976 | $87,152 | $42,879 |
| Enterprise Value | $259,989 | $224,855 | $345,682 | $1,449,299 |
| Revenue | $35,584 | $20,756 | $31,096 | $45,785 |
| % Growth | 71.4% | -33.3% | -32.1% | – |
| Gross Profit | $35,584 | $13,019 | $31,096 | $45,785 |
| % Margin | 100% | 62.7% | 100% | 100% |
| EBITDA | -$103,367 | -$122,103 | -$124,283 | -$80,255 |
| % Margin | -290.5% | -588.3% | -399.7% | -175.3% |
| Net Income | -$105,316 | -$132,493 | -$128,175 | -$83,892 |
| % Margin | -296% | -638.3% | -412.2% | -183.2% |
| EPS Diluted | -1.52 | -2.67 | -2.62 | -1.82 |
| % Growth | 43.1% | -1.9% | -44% | – |
| Operating Cash Flow | -$65,157 | -$106,838 | -$105,939 | -$86,965 |
| Capital Expenditures | -$180 | -$1,708 | -$5,496 | -$1,277 |
| Free Cash Flow | -$65,337 | -$108,546 | -$111,435 | -$88,242 |